Summary
AbbVie Inc. (ABBV) announced through an 8-K filing on August 5, 2026, the closing of a significant debt offering totaling approximately $9.93 billion in net proceeds. This substantial capital raise comprises multiple tranches of senior notes with varying maturities and interest rates, including floating rate notes, fixed-rate notes ranging from 2028 to 2066. The primary purpose of this offering is to fund a portion of the cash payment obligations related to AbbVie's acquisition of Apogee Therapeutics, Inc. This strategic move underscores AbbVie's commitment to its growth strategy through significant M&A activity. The proceeds will also be used for other general corporate purposes, potentially including debt repayment or repurchase, and will reduce commitments under an existing term loan facility established for the Apogee acquisition.
Key Highlights
- 1AbbVie raised approximately $9.93 billion in net proceeds from the issuance of various senior notes.
- 2The debt offering includes a mix of floating rate notes and fixed-rate notes with maturities spanning from 2028 to 2066.
- 3The net proceeds are primarily earmarked to finance part of the cash consideration for the acquisition of Apogee Therapeutics, Inc.
- 4The offering also allows for general corporate purposes, which may include debt reduction.
- 5This capital raise reduces AbbVie's reliance on a previously established $10.0 billion term loan facility for the Apogee acquisition.
- 6The underwriting agreement with major financial institutions, including Morgan Stanley, BofA Securities, and J.P. Morgan, contains customary representations, warranties, and indemnification clauses.